Halozyme Therapeutics HALO Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's long-term debt?
- Halozyme Therapeutics (HALO) reported long-term debt of $1.94B in Q1 2026.
- How has Halozyme Therapeutics's long-term debt changed year-over-year?
- Halozyme Therapeutics's long-term debt increased by 28.4% year-over-year, from $1.51B to $1.94B.
- What does long-term debt mean?
- Debt obligations that are not due for payment within the next year.
- How do you interpret long-term debt?
- Higher levels increase financial leverage and interest expense, while lower levels reduce solvency risk but may limit growth capital.
- How does long-term debt compare across companies?
- Benchmark against debt-to-equity ratios of peers in the same sector.